by InSitu Biologics | Dec 28, 2021 | News & Updates
InSitu Biologics is closing out 2021 with many accomplishments. We received positive pre-IND feedback from the FDA, made gains in process development work, published and presented INSB200™ data, and closed an additional institutional funding round. For additional...
by InSitu Biologics | Oct 29, 2021 | News & Updates
The American Society of Regional Anesthesia has chosen InSitu Biologics’ INSB200™ poster as a Best of Meeting presentation in Emerging Technologies for their 20th Annual Pain Meeting in November 2021. For additional information regarding this selection, please take...
by InSitu Biologics | Aug 9, 2021 | News & Updates
InSitu Biologics has had a very productive summer. We received positive pre-clinical animal study results on our lead product, had positive regulatory interactions with the FDA, further developed our manufacturing capabilities, and made progress towards future funding...
by InSitu Biologics | Apr 15, 2021 | General
InSitu Biologics is off to a fast start in 2021. We completed a successful financing round, made great strides in our R&D efforts, and held our first Medical Advisory Board meeting. For additional information regarding our progress, please take some time to read...
by InSitu Biologics | Dec 18, 2020 | General
Insitu Biologics had several key accomplishments in 2020, setting the stage for an even better 2021. We significantly reduced our shareholders-of-record, renegotiated and renewed our license agreement with LifeCore Biomedical, and conducted successful bench and animal...
